俄駐華大使:中國疫苗在俄臨床初步結果「非常好」
據《北京晚報》報道,在俄羅斯駐華使館昨日(29日)舉行的2020年年度新聞發布會上,駐華大使安德烈-傑尼索夫表示,中國供應商提供的醫療物資幫助俄羅斯渡過了疫情發生以來最困難的時期,中國公司在俄羅斯進行疫苗臨床試驗,試驗結果「非常好」。
傑尼索夫介紹了兩國在新冠疫苗領域的合作情況。他表示,疫苗涉及到非常複雜的研究和技術,在國際合作慣例當中,疫苗合作非常少見。
他表示,俄中兩國在新冠疫苗領域開展務實合作。中國康希諾生物(06185.HK)研制的疫苗是第一個獲得俄羅斯衛生部許可,在俄羅斯進行臨床試驗的疫苗。8,000名志願者接受了臨床試驗,目前相關試驗已經完成,正在對數據進行分析。根據俄方了解,初步的試驗結果非常好。
傑尼索夫還透露,俄羅斯方面還與中國醫療機構合作,計劃在中國生產俄羅斯新冠疫苗「衛星V」。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.